NVAX - Novavax, Inc.
| Previous close | 52.82 |
| Open | 52.74 |
| Bid | 49.26 x 1000 |
| Ask | 49.50 x 900 |
| Day's range | 47.66 - 52.61 |
| 52-week range | 3.54 - 61.50 |
| Volume | 6,538,764 |
| Avg. volume | 9,915,093 |
| Market cap | 2.912B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.83 |
| Earnings date | 11 May 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 49.20 |
- Motley Fool
Better Coronavirus Stock: Gilead Sciences or Novavax?
Between a big biotech with the leading COVID-19 therapy and a small biotech with a promising COVID-19 vaccine candidate, which stock wins?
- Motley Fool
Why Novavax Shares Soared Today
What happened Shares of Novavax (NASDAQ: NVAX) were soaring 14.9% as of 3 p.m. EDT on Monday. The big jump came after B. Riley FBR analyst Mayank Mamtani boosted his 12-month price target on the biotech stock to $61 per share from $53.
- Zacks
5 Top Stocks Up 100%+ in May With More Room to Run
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
- Motley Fool
Buy Alert: Novavax Stock Is Heading Higher
Speculators are buying up shares of Novavax, based on a vast market opportunity for its COVID-19 vaccine. But there's even better news that largely mitigates any downside risk.
- Yahoo Finance
How Novavax is pulling out all the stops to produce a coronavirus vaccine by next year
If all goes according to plan, Novavax anticipates being able to produce 100 million doses in 2020, mostly for frontline workers, and 1 billion doses by 2021.
- Yahoo Finance
ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
- Motley Fool
Coronavirus 2020: Where to Invest $500 Right Now
These three stocks are leaders in the fight against COVID-19 and have compelling growth prospects beyond their coronavirus programs.
- Motley Fool
Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity
After acquiring a Czech company, the clinical-stage biotech will be able to churn out more than 1 billion doses of its SARS-CoV-2 vaccine candidate next year -- if it works.
- Zacks
Biotech ETFs Soaring on COVID-19 Vaccine Progress
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.
- Zacks
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
- Zacks
S&P Reclaims 3,000 Mark: Go Long With These ETFs
Wall Street is rallying this quarter with the S&P 500 reclaiming its 3,000 level.
- Reuters
Novavax aims to make 1 billion COVID-19 vaccine doses after buying plant
The U.S. company said on Wednesday it would buy Czech Republic-based Praha Vaccines, a unit of India's Cyrus Poonawalla Group, which also owns Serum Institute, for $167 million in cash. Novavax is one of several companies in the race to develop a vaccine for COVID-19, the disease caused by the novel coronavirus, that has no current treatment or vaccine and has already killed about 350,000 people.
- Zacks
Stock Market News for May 27, 2020
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
- Zacks
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
- Motley Fool
Why Moderna Is Dropping Today
Another biotech company is hot on Moderna's trail in the race to develop a vaccine for the novel coronavirus.
- Yahoo Finance
Coronavirus update: Novavax begins vaccine trials; Brazil reports second-highest number of cases in world
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
- Yahoo Finance
Novavax expects COVID-19 vaccine trial results in July
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
- Motley Fool
Novavax Begins Early Stage Clinical Study of Its Coronavirus Vaccine Candidate
Novavax (NASDAQ: NVAX) announced on Monday that it had begun enrolling participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate NVX-CoV2373. The vaccine candidate demonstrated promising results in preclinical testing, including a significant immune system response and high levels of neutralizing antibodies, which bind to the novel coronavirus and block infection. The clinical study will consist of two parts.
- Zacks
Pre-Markets Race Higher on Vaccine Hopes
Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.
- Zacks
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
- Zacks
Novavax Begins Clinical Study for Coronavirus Vaccine
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
- Motley Fool
Why Novavax Stock Is Skyrocketing Today
Shares of Novavax (NASDAQ: NVAX), a clinical-stage vaccine company, are poised to continue their amazing run today. Novavax's shares are heating up yet again this morning in response to the official start of the combined phase 1/2 trial for the company's COVID-19 vaccine candidate, NVX‑CoV2373. Novavax's shares have now gained well over 1,000% since the start of 2020, thanks mainly to the excitement surrounding NVX‑CoV2373.
- Zacks
2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks
As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.
- Zacks
Coronavirus Vaccine Development Gathers Steam: 4 Winners
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
